Skip to content

Marker Therapeutics, Inc.

MRKR

CIK 0001094038

← back to feed
Revenue (TTM)
$205.99K
−100.0% YoY Q1 May 2026
Net Income (TTM)
−$13.64M
−13.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.97
+33.6% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-7,489.6%
Q1 May 2026
Net Margin
-6,621.4%
Q1 May 2026
Free Cash Flow (TTM)
−$17M
Q1 May 2026
Cash
$14.92M
Q1 May 2026
Total Debt
$67.94K
Q1 May 2026
Shares Outstanding
16.67M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings